AstraZeneca Truqap plus Faslodex gets nod in Japan for advanced HR-positive breast cancer
Cambridge: AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in Japan for the treatment of adult patients with unresectable or recurrent PIK3CA, AKT1, or PTEN-altered hormone receptor (HR)-positive, HER2-negative breast cancer following progression after treatment with endocrine therapy. The approval by the Japanese Ministry of Health, Labour, and Welfare (MHLW) was based […]